Cargando…

Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor

BACKGROUND: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measurement. OBJECTIVES: We conducted this study to identify the prognostic factors for successful treatment-free remission in patients with chronic-phase chronic myeloid leukemia who discontinued tyrosine kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyunkyung, Kim, Hyeong-Joon, Sohn, Sang-Kyun, Baik, Yoonsuk, Kim, Dongho, Lee, Sung-Yeoun, Kong, Jee Hyun, Kim, Hawk, Shin, Dong-Yeop, Ahn, Jae-Sook, Park, Jinny, Park, Seonyang, Kim, Inho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624046/ https://www.ncbi.nlm.nih.gov/pubmed/37929079 http://dx.doi.org/10.1177/20406207231205637

Ejemplares similares

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
por: Kim, Jinyong, et al.
Publicado: (2021)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
por: Kim, Yeojae, et al.
Publicado: (2022)

Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay
por: Chung, Hee-Jung, et al.
Publicado: (2020)

Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
por: Bochicchio, Maria Teresa, et al.
Publicado: (2021)

The e8a2 fusion transcript in B lymphoblastic leukemia with BCR-ABL1 rearrangement
por: Kim, Min Jin, et al.
Publicado: (2012)

Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
por: Serpa, Mariana, et al.
Publicado: (2010)

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
por: Dragani, Matteo, et al.
Publicado: (2020)

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
por: Di Giusto, Sara, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
por: Fokoloros, Christos, et al.
Publicado: (2022)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
por: Lee, Je-Hwan, et al.
Publicado: (2010)

Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
por: Kim, Heejeong, et al.
Publicado: (2023)

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea.
por: Kim, Inho, et al.
Publicado: (2003)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
por: Bang, Soo-Mee, et al.
Publicado: (2006)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
por: Song, Gyun Jee, et al.
Publicado: (2019)

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
por: Feldhahn, Niklas, et al.
Publicado: (2012)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea
por: Shin, Junghoon, et al.
Publicado: (2018)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h9ranc59sdql3d6vev3fvkgito